Pfizer Submits Application For Additional Indication Of Solu Medrol In Japan
This article was originally published in PharmAsia News
Executive Summary
Pfizer submitted a public knowledge-based application in Japan on Sept. 12 for an additional indication for Solu-Medrol (methylprednisolone) for treatment of acute exacerbation of multiple sclerosis.